Table 2.
Timing of clinical events in 199 patients hospitalised with severe dengue in 2014
| All (N = 199) | Died (N = 20) | Survived (N = 179) | p-value | ||||
|---|---|---|---|---|---|---|---|
| n | n (%) or median (IQR) | n | n (%) or median (IQR) | n | n (%) or median (IQR) | ||
| 1Day of admission | 199 | 4.00 (2.81–5.00) | 20 | 3.51 (2.58–4.38) | 179 | 4.03 (2.93–5.00) | 0.29 |
| 2Day of development of severe dengue | 198 | 4.63 (3.56–5.67) | 20 | 4.07 (3.22–5.81) | 178 | 4.65 (3.66–5.67) | 0.39 |
| 3Day of defervescence | 194 | 4.96 (3.92–6.04) | 18 | 4.08 (3.00–5.13) | 176 | 5.02 (4.03–6.13) | 0.05 |
| 4Day of outcome | 199 | 8.75 (7.16–11.0) | 20 | 6.81 (4.91–12.82) | 179 | 8.80 (7.46–10.67) | 0.08 |
| Phase at admission, febrile | 194 | 153 (78.8) | 18 | 10 (55.6) | 176 | 143 (81.3) | 0.03a |
| Phase at severe dengue diagnosis, febrile | 193 | 114 (59.1) | 18 | 6 (33.3) | 175 | 108 (61.7) | 0.02 |
| Severe dengue upon presentation | 198 | 73 (36.9) | 20 | 8 (40.0) | 178 | 65 (36.5) | 0.76 |
| 5Day of nadir WBC | 199 | 4.63 (3.75–5.71) | 20 | 3.74 (2.93–5.34) | 179 | 4.71 (3.88–5.73) | 0.07 |
| 6Day of nadir platelet | 199 | 5.50 (4.64–6.50) | 20 | 4.79 (3.40–6.96) | 179 | 5.54 (4.79–6.50) | 0.11 |
| 7Day of lowest serum bicarbonate | 197 | 5.00 (3.92–6.04) | 20 | 5.36 (3.56–8.94) | 177 | 4.92 (3.96–5.92) | 0.15 |
| 8Day of highest serum lactate | 190 | 5.38 (4.13–6.60) | 20 | 5.44 (3.93–9.70) | 170 | 5.35 (4.13–6.50) | 0.32 |
| 9Day of highest serum ALT | 198 | 5.56 (4.42–6.75) | 20 | 5.41 (4.05–7.02) | 178 | 5.58 (4.42–6.75) | 0.88 |
| 10Day of highest serum AST | 194 | 5.35 (4.29–6.54) | 20 | 5.26 (4.18–7.39) | 174 | 5.35 (4.38–6.50) | 0.81 |
| 11Day of highest serum creatinine | 199 | 4.67 (3.67–5.79) | 20 | 4.81 (4.00–8.38) | 179 | 4.67 (3.58–5.71) | 0.10 |
n count of non-missing observations; aFisher’s exact test; IQR interquartile range, WBC white blood cell count, AST aspartate transaminase, ALT alanine transaminase; 1–11 These are days from onset of fever